Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2017 14:20 ET | Source: AC Immune SA

AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases

Lausanne, Switzerland, December 1, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, shared...
November 21, 2017 08:31 ET | Source: AC Immune SA

AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases

Lausanne, Switzerland, November 21, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
November 13, 2017 06:47 ET | Source: AC Immune SA

AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update

Expansion of pipeline with two new antibodies against proteins alpha-synuclein and TDP-43 Recruitment of first cohort completed for anti-beta vaccine targeting Alzheimer's symptoms in adults...
November 02, 2017 06:22 ET | Source: AC Immune SA

AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease

AC Immune to receive third milestone payment of CHF 14 million under collaboration agreement with Genentech Phase 2 to evaluate effects of anti-Tau antibody in...
October 24, 2017 05:40 ET | Source: AC Immune SA

AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference

AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference Lausanne, Switzerland, - October 24, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based,...
October 03, 2017 04:53 ET | Source: AC Immune SA

AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinson's Research

Continued development of PET tracer for earlier and more accurate diagnosis of Parkinson's disease Focuses on alpha-synuclein, a key protein in Parkinson's disease pathology Lausanne,...
September 12, 2017 06:04 ET | Source: AC Immune SA

AC IMMUNE COMPLETES RECRUITMENT FOR LOW-DOSE COHORT IN WORLD'S FIRST CLINICAL TRIAL FOR ANTI-ABETA VACCINE TARGETING ALZHEIMER'S DISEASE-LIKE CHARACTERISTICS IN INDIVIDUALS WITH DOWN SYNDROME

AC Immune completes Recruitment for Low-Dose Cohort of Participants in World's First Clinical Trial for anti-Abeta Vaccine Targeting Alzheimer's Disease-like Characteristics in Individuals with Down...
August 22, 2017 04:24 ET | Source: AC Immune SA

AC IMMUNE DISCOVERS NEXT-GENERATION ANTIBODIES FOCUSED ON NEURODEGENERATIVE DISEASES

Pipeline expansion with new antibodies against alpha-synuclein and TDP-43 Proprietary scientific approach rapidly delivers high-quality assets Execution of clear strategy around three pillars ...
August 09, 2017 06:44 ET | Source: AC Immune SA

AC IMMUNE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS

Strong cash position of CHF 124.2 million provides resources to advance pipeline of seven therapeutic and three diagnostic candidates Increased R&D investment across three pillars of...
July 10, 2017 07:55 ET | Source: AC Immune SA

AC IMMUNE PROVIDES SEVEN UPDATES ON ITS PIPELINE AND TECHNOLOGY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE

Lausanne, Switzerland, July 10, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that seven updates...